| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary target of n-Butyl-β-D-fructofuranoside appears to be the mitochondrial pathway involved in apoptosis. In Bel-7402 cells, the compound induces apoptosis, as evidenced by changes in the expression of key apoptotic regulators: Bcl-2 levels gradually diminish, while Bax and p53 levels increase. This shift in the Bcl-2/Bax ratio favors apoptosis. The compound also interferes with the cell cycle, causing arrest in the G0/G1 phase. Its specific molecular target within these pathways has not been identified.
|
|---|---|
| ln Vitro |
The anti-proliferative activity of n-Butyl-β-D-fructofuranoside (0-23.6 μg/mL; 24-78 hours) decreases the viability of Bel-7402 cells [1]. BEL-7402 cells are inhibited by n-Butyl-β-D-fructofuranoside (0-75 μg/mL; 0-72 hours) through apoptosis induction and cell cycle interference [1].
In vitro, n-Butyl-β-D-fructofuranoside demonstrates antiproliferative activity against Bel-7402 cells. At concentrations of 0-23.6 μg/mL and incubation times of 24-78 hours, it decreases cell viability in a time- and dose-dependent manner. Cell cycle analysis shows that at concentrations of 0, 50, and 75 μg/mL, the compound induces cell cycle arrest in the G0/G1 phase. Western blot analysis at 23.6 μg/mL reveals that Bcl-2 levels gradually decrease while Bax and p53 levels increase over 0-72 hours. |
| ln Vivo |
Specific in vivo activity data for n-Butyl-β-D-fructofuranoside are not provided in the available sources. While the compound exhibits promising in vitro antiproliferative and apoptosis-inducing activity, no in vivo studies in animal models are described. Further research would be needed to evaluate its efficacy, pharmacokinetics, and safety in vivo. Its potential for cancer research has been suggested based on its in vitro activity.
|
| Enzyme Assay |
A cell-free assay for n-Butyl-β-D-fructofuranoside is not described in the available sources, as its activity is characterized through cell-based assays. The compound's mechanism of action involves apoptosis induction and cell cycle interference, which are typically assessed in cellular systems rather than cell-free enzymatic assays. Its effects on apoptotic markers (Bcl-2, Bax, p53) are measured in cell lysates using techniques such as Western blotting.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Bel-7402 Cell Tested Concentrations: 0.47, 2.95, 5.90, 11.8, 17.7 and 23.6 μg/mL Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: Inhibition of Bel-7402 at both concentrations Cells proliferated in a time- and dose-dependent manner. Cell cycle analysis [1] Cell Types: Bel-7402 Cell Tested Concentrations: 0, 50 and 75 μg/mL Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: Induced cell cycle arrest in G0/G1 phase. Western Blot Analysis[1] Cell Types: Bel-7402 Cell Tested Concentrations: 23.6 μg/mL Incubation Duration: 0, 24, 48 and 72 hrs (hours) Experimental Results: Bcl-2 levels gradually diminished, and Bax and p53 levels increased. In vitro cellular experiments with n-Butyl-β-D-fructofuranoside typically use Bel-7402 hepatocellular carcinoma cells. For cell viability assays, cells are treated with concentrations of 0.47, 2.95, 5.90, 11.8, 17.7, and 23.6 μg/mL for 24, 48, and 72 hours. For cell cycle analysis, concentrations of 0, 50, and 75 μg/mL are used for 24, 48, and 72 hours. For Western blot analysis, cells are treated with 23.6 μg/mL for 0, 24, 48, and 72 hours. The compound's effects are assessed through viability assays, cell cycle distribution analysis, and protein expression analysis. |
| Animal Protocol |
Specific in vivo animal实验 protocols for n-Butyl-β-D-fructofuranoside are not available from the provided sources. As a compound with in vitro anticancer activity, potential in vivo studies could involve xenograft models in mice, where tumor-bearing animals would be treated with the compound to evaluate tumor growth inhibition. However, no such data or protocols are described in the accessible literature. The compound is currently only characterized in cell-based assays.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of n-Butyl-β-D-fructofuranoside are not reported in the available sources. As a naturally occurring compound, its absorption, distribution, metabolism, and excretion (ADME) profiles have not been characterized. General storage recommendations include keeping the powder at -20°C for up to 3 years or at 4°C for up to 2 years. Solutions should be stored at -80°C for up to 6 months or at -20°C for up to 1 month. The compound requires protection from light. It is soluble in DMSO at approximately 100 mg/mL.
|
| Toxicity/Toxicokinetics |
Toxicity data for n-Butyl-β-D-fructofuranoside are not provided in the available sources. The compound is described as having antiproliferative activity against cancer cells, but no specific toxicological information is available. As with all research compounds, it is intended for research use only and not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
According to reports, butylfructofuranoside has been found in Cynomorium songaricum, Dioscorea japonica, and Ophiopogon japonicus, and relevant data are available for reference.
n-Butyl-β-D-fructofuranoside (CAS: 80971-60-4) is a naturally occurring compound extracted from Kangaisan, a traditional herbal medicine. Its别名 include Butyl fructofuranoside and Butyl-beta-d-fructofuranoside. The compound has been studied for its potential in cancer research due to its ability to induce apoptosis through the mitochondrial pathway and interfere with the cell cycle. It is not an approved drug and has not undergone clinical trials. Its primary value lies in its use as a tool for studying apoptosis and cell cycle regulation in cancer cells. The compound is available from research chemical suppliers for non-clinical research purposes only. |
| Molecular Formula |
C10H20O6
|
|---|---|
| Molecular Weight |
236.262204170227
|
| Exact Mass |
236.126
|
| CAS # |
80971-60-4
|
| PubChem CID |
13386213
|
| Appearance |
Light yellow to yellow ointment
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
16
|
| Complexity |
212
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCCCOC1(C(C(C(O1)CO)O)O)CO
|
| InChi Key |
XRGRZXPJJVQDJO-DOLQZWNJSA-N
|
| InChi Code |
InChI=1S/C10H20O6/c1-2-3-4-15-10(6-12)9(14)8(13)7(5-11)16-10/h7-9,11-14H,2-6H2,1H3/t7-,8-,9+,10-/m1/s1
|
| Chemical Name |
(2R,3S,4S,5R)-2-butoxy-2,5-bis(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~423.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2326 mL | 21.1631 mL | 42.3263 mL | |
| 5 mM | 0.8465 mL | 4.2326 mL | 8.4653 mL | |
| 10 mM | 0.4233 mL | 2.1163 mL | 4.2326 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
